Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Accounts Payables (2021 - 2025)

Historic Accounts Payables for Krystal Biotech (KRYS) over the last 5 years, with Q3 2025 value amounting to $31.7 million.

  • Krystal Biotech's Accounts Payables fell 4030.5% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.7 million, marking a year-over-year decrease of 4030.5%. This contributed to the annual value of $59.0 million for FY2024, which is 17422.71% up from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Accounts Payables is $31.7 million, which was down 4030.5% from $26.5 million recorded in Q2 2025.
  • Krystal Biotech's Accounts Payables' 5-year high stood at $59.0 million during Q4 2024, with a 5-year trough of $6.7 million in Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $26.5 million (2025), whereas its average is $28.9 million.
  • Per our database at Business Quant, Krystal Biotech's Accounts Payables surged by 66393.57% in 2022 and then plummeted by 4211.78% in 2023.
  • Over the past 5 years, Krystal Biotech's Accounts Payables (Quarter) stood at $16.3 million in 2021, then surged by 43.0% to $23.3 million in 2022, then dropped by 7.7% to $21.5 million in 2023, then soared by 174.23% to $59.0 million in 2024, then plummeted by 46.25% to $31.7 million in 2025.
  • Its Accounts Payables was $31.7 million in Q3 2025, compared to $26.5 million in Q2 2025 and $28.0 million in Q1 2025.